Inflammation and Alzheimer's disease: Possible role of periodontal diseases
Corresponding Author
Angela R. Kamer
- [email protected]
- 212-998-9868 | Fax: 212-995-4603
Department of Periodontology and Implant Dentistry, College of Dentistry, New York University, New York, NY, USA
Corresponding author. Tel.: 212-998-9868; fax: 212-995-4603.
E-mail address: [email protected]
Search for more papers by this authorRonald G. Craig
Department of Periodontology and Implant Dentistry, College of Dentistry, New York University, New York, NY, USA
Department of Basic Sciences and Craniofacial Biology, College of Dentistry, New York University, New York, NY, USA
Search for more papers by this authorAnanda P. Dasanayake
Department of Epidemiology and Health Promotion, College of Dentistry, New York University, New York, NY, USA
Search for more papers by this authorMiroslaw Brys
Department of Psychiatry, School of Medicine, New York University, New York, NY, USA
Search for more papers by this authorLidia Glodzik-Sobanska
Department of Psychiatry, School of Medicine, New York University, New York, NY, USA
Search for more papers by this authorMony J. de Leon
Department of Psychiatry, School of Medicine, New York University, New York, NY, USA
Nathan Kline Institute, Orangeburg, NY, USA
Search for more papers by this authorCorresponding Author
Angela R. Kamer
- [email protected]
- 212-998-9868 | Fax: 212-995-4603
Department of Periodontology and Implant Dentistry, College of Dentistry, New York University, New York, NY, USA
Corresponding author. Tel.: 212-998-9868; fax: 212-995-4603.
E-mail address: [email protected]
Search for more papers by this authorRonald G. Craig
Department of Periodontology and Implant Dentistry, College of Dentistry, New York University, New York, NY, USA
Department of Basic Sciences and Craniofacial Biology, College of Dentistry, New York University, New York, NY, USA
Search for more papers by this authorAnanda P. Dasanayake
Department of Epidemiology and Health Promotion, College of Dentistry, New York University, New York, NY, USA
Search for more papers by this authorMiroslaw Brys
Department of Psychiatry, School of Medicine, New York University, New York, NY, USA
Search for more papers by this authorLidia Glodzik-Sobanska
Department of Psychiatry, School of Medicine, New York University, New York, NY, USA
Search for more papers by this authorMony J. de Leon
Department of Psychiatry, School of Medicine, New York University, New York, NY, USA
Nathan Kline Institute, Orangeburg, NY, USA
Search for more papers by this authorAbstract
The molecular and cellular mechanisms responsible for the etiology and pathogenesis of Alzheimer's disease (AD) have not been defined; however, inflammation within the brain is thought to play a pivotal role. Studies suggest that peripheral infection/inflammation might affect the inflammatory state of the central nervous system. Chronic periodontitis is a prevalent peripheral infection that is associated with gram-negative anaerobic bacteria and the elevation of serum inflammatory markers including C-reactive protein. Recently, chronic periodontitis has been associated with several systemic diseases including AD. In this article we review the pathogenesis of chronic periodontitis and the role of inflammation in AD. In addition, we propose several potential mechanisms through which chronic periodontitis can possibly contribute to the clinical onset and progression of AD. Because chronic periodontitis is a treatable infection, it might be a readily modifiable risk factor for AD.
References
- [1]L.E. Nee, C.F. Lippa. Alzheimer's disease in 22 twin pairs: 13-year follow-up—hormonal, infectious and traumatic factors. Dement Geriatr Cogn Disord. 10: 1999; 148–151
- [2]P.L. McGeer, E.G. McGeer. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging. 22: 2001; 799–809
- [3]H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 21: 2000; 383–421
- [4]J.P. Konsman, B. Drukarch, A.M. Van Dam. (Peri)vascular production and action of pro-inflammatory cytokines in brain pathology. Clin Sci (Lond). 112: 2007; 1–25
- [5]D. Gosselin, S. Rivest. Role of IL-1 and TNF in the brain: twenty years of progress on a Dr Jekyll/Mr Hyde duality of the innate immune system. Brain Behav Immun. 21: 2007; 281–289
- [6]M.J. Engelhart, M.I. Geerlings, J. Meijer, A. Kiliaan, A. Ruitenberg, J.C. van Swieten, et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol. 61: 2004; 668–672
- [7]K. Yaffe, A. Kanaya, K. Lindquist, E.M. Simonsick, T. Harris, R.I. Shorr, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 292: 2004; 2237–2242
- [8]R. Schmidt, H. Schmidt, J.D. Curb, K. Masaki, L.R. White, L.J. Launer. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 52: 2002; 168–174
- [9]J. Kalman, A. Juhasz, G. Laird, P. Dickens, T. Jardanhazy, A. Rimanoczy, et al. Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease. Acta Neurol Scand. 96: 1997; 236–240
- [10]C. Holmes, M. El-Okl, A.L. Williams, C. Cunningham, D. Wilcockson, V.H. Perry. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 74: 2003; 788–789
- [11]J.A. Nicoll, R.E. Mrak, D.I. Graham, J. Stewart, G. Wilcock, S. MacGowan, et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol. 47: 2000; 365–368
- [12]B.A. in't Veld, A. Ruitenberg, A. Hofman, B.H. Stricker, M.M. Breteler. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging. 22: 2001; 407–412
- [13]W.F. Stewart, C. Kawas, M. Corrada, E.J. Metter. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48: 1997; 626–632
- [14]P.L. McGeer, E.G. McGeer. Anti-inflammatory drugs in the fight against Alzheimer's disease. Ann N Y Acad Sci. 777: 1996; 213–220
- [15]P.S. Aisen, K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K.L. Davis, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 289: 2003; 2819–2826
- [16]L.J. Thal, S.H. Ferris, L. Kirby, G.A. Block, C.R. Lines, E. Yuen, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 30: 2005; 1204–1215
- [17]K.P. Townsend, D. Pratico. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. Faseb J. 19: 2005; 1592–1601
- [18]R. von Bernhardi, J. Eugenin. Microglial reactivity to beta-amyloid is modulated by astrocytes and proinflammatory factors. Brain Res. 1025: 2004; 186–193
- [19]R. Dantzer, J.P. Konsman, R.M. Bluthe, K.W. Kelley. Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent? Auton Neurosci. 85: 2000; 60–65
- [20]A.J. Miller, G.N. Luheshi, N.J. Rothwell, S.J. Hopkins. Local cytokine induction by LPS in the rat air pouch and its relationship to the febrile response. Am J Physiol. 272 (Pt 2): 1997; R857–R861
- [21]S. Rivest. Molecular insights on the cerebral innate immune system. Brain Behav Immun. 17: 2003; 13–19
- [22]R.F. Itzhaki, M.A. Wozniak, D.M. Appelt, B.J. Balin. Infiltration of the brain by pathogens causes Alzheimer's disease. Neurobiol Aging. 25: 2004; 619–627
- [23]A.J. Lerner, P. Hedera, E. Koss, J. Stuckey, R.P. Friedland. Delirium in Alzheimer disease. Alzheimer Dis Assoc Disord. 11: 1997; 16–20
- [24]B.J. Balin, H.C. Gerard, E.J. Arking, D.M. Appelt, P.J. Branigan, J.T. Abrams, et al. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol (Berl). 187: 1998; 23–42
- [25]J. Miklossy, A. Kis, A. Radenovic, L. Miller, L. Forro, R. Martins, et al. Beta-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol Aging. 27: 2006; 228–236
- [26]R.P. Ellen, V.B. Galimanas. Spirochetes at the forefront of periodontal infections. Periodontol 2000. 38: 2005; 13–32
- [27]G.R. Riviere, K.H. Riviere, K.S. Smith. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease. Oral Microbiol Immunol. 17: 2002; 113–118
- [28]F. Foschi, J. Izard, H. Sasaki, V. Sambri, C. Prati, R. Muller, et al. Treponema denticola in disseminating endodontic infections. J Dent Res. 85: 2006; 761–765
- [29]M.A. Taubman, P. Valverde, X. Han, T. Kawai. Immune response: the key to bone resorption in periodontal disease. J Periodontol. 76 (Suppl): 2005; 2033–2041
10.1902/jop.2005.76.11-S.2033 Google Scholar
- [30]J.M. Albandar. Periodontal diseases in North America. Periodontol 2000. 29: 2002; 31–69
- [31]S.S. Socransky, A.D. Haffajee. Dental biofilms: difficult therapeutic targets. Periodontol 2000. 28: 2002; 12–55
- [32]K.S. Kornman, R.C. Page, M.S. Tonetti. The host response to the microbial challenge in periodontitis: assembling the players. Periodontol 2000. 14: 1997; 33–53
- [33]K.S. Kornman. Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging. Am J Clin Nutr. 83: 2006; 475S–483S
- [34]F.A. Scannapieco, R.B. Bush, S. Paju. Associations between periodontal disease and risk for nosocomial bacterial pneumonia and chronic obstructive pulmonary disease: a systematic review. Ann Periodontol. 8: 2003; 54–69
- [35]E.E. Zijlstra, G.R. Swart, F.J. Godfroy, J.E. Degener. Pericarditis, pneumonia and brain abscess due to a combined Actinomyces–Actinobacillus actinomycetemcomitans infection. J Infect. 25: 1992; 83–87
- [36]A.P. Dasanayake, S. Russell, D. Boyd, P.N. Madianos, T. Forster, E. Hill. Preterm low birth weight and periodontal disease among African Americans. Dent Clin North Am. 47: 2003; 115–125, x–xi
- [37]J.D. Beck, S. Offenbacher. Systemic effects of periodontitis: epidemiology of periodontal disease and cardiovascular disease. J Periodontol. 76 (Suppl): 2005; 2089–2100
10.1902/jop.2005.76.11-S.2089 Google Scholar
- [38]G.W. Taylor. Bidirectional interrelationships between diabetes and periodontal diseases: an epidemiologic perspective. Ann Periodontol. 6: 2001; 99–112
- [39]M.M.J. Gatz, L. Fratiglioni, B. Johansson, S. Berg, C.A. Reynolds, N.L. Pedersen. Potentially modifiable risk factors for dementia in identical twins. Alzheimer's & Dementia: the Journal of the Alzheimer's Association. 2: 2006; 110–117
- [40]V. Lucas, G.J. Roberts. Odontogenic bacteremia following tooth cleaning procedures in children. Pediatr Dent. 22: 2000; 96–100
- [41]K. Okuda, K. Ishihara, T. Nakagawa, A. Hirayama, Y. Inayama, K. Okuda. Detection of Treponema denticola in atherosclerotic lesions. J Clin Microbiol. 39: 2001; 1114–1117
- [42]P.J. Pussinen, P. Jousilahti, G. Alfthan, T. Palosuo, S. Asikainen, V. Salomaa. Antibodies to periodontal pathogens are associated with coronary heart disease. Arterioscler Thromb Vasc Biol. 23: 2003; 1250–1254
- [43]M. Desvarieux, R.T. Demmer, T. Rundek, B. Boden-Albala, D.R. Jacobs Jr, R.L. Sacco, et al. Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation. 111: 2005; 576–582
- [44]M. Ide, D. Jagdev, P.Y. Coward, M. Crook, G.R. Barclay, R.F. Wilson. The short-term effects of treatment of chronic periodontitis on circulating levels of endotoxin, C-reactive protein, tumor necrosis factor-alpha, and interleukin-6. J Periodontol. 75: 2004; 420–428
- [45]R.G. Craig, J.K. Yip, M.K. So, R.J. Boylan, S.S. Socransky, A.D. Haffajee. Relationship of destructive periodontal disease to the acute-phase response. J Periodontol. 74: 2003; 1007–1016
- [46]G.D. Slade, S. Offenbacher, J.D. Beck, G. Heiss, J.S. Pankow. Acute-phase inflammatory response to periodontal disease in the US population. J Dent Res. 79: 2000; 49–57
- [47]S. Offenbacher. Periodontal diseases: pathogenesis. Ann Periodontol. 1: 1996; 821–878
- [48]E.G. McGeer, P.L. McGeer. Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. Mol Interv. 1: 2001; 22–29
- [49]P.L. McGeer, E.G. McGeer. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 28: 2007; 639–647
- [50]M.J. de Leon, S. DeSanti, R. Zinkowski, P.D. Mehta, D. Pratico, S. Segal, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 27: 2006; 394–401